Search
Zevra Therapeutics Inc
ZVRAAdd to Watchlist
12.900USD
+0.290+2.30%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
762.58MMarket Cap
6.12P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Zevra Therapeutics Inc is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 26.00 and a low of 18.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
28.250
Target Price
+118.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Zevra Therapeutics Inc
ZVRA
9
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Zevra Therapeutics Inc's expected revenue for the next quarter?
Zevra Therapeutics Inc's expected revenue is 34.02M.
What is Zevra Therapeutics Inc's price target?
Analysts forecast that Zevra Therapeutics Inc's price target is USD 24.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 18.00.
How have Zevra Therapeutics IncZVRA's recent earnings per share performed?
The market expectation was USD 0.65, while Zevra Therapeutics IncZVRA's earnings per share (EPS) for the previous quarter was USD 0.21. EPS for the next quarter is expected at USD 0.09.
What is the analyst rating for Zevra Therapeutics Inc?
Based on the ratings of Zevra Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
